Noncommunicable diseases in HIV infection in low-and middle-income countries: Gastrointestinal, hepatic, and nutritional aspects

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue SUPPL.1, 2014, Pages

  Kelly, Paul ^a,b   Saloojee, Haroon ^c   Chen, Jennifer Y ^d   Chung, Raymond T ^d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF ZAMBIA   (Zambia)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

digestive disorders; HIV; liver disorders; malnutrition; noncommunicable disease

Indexed keywords

ARTICLE; BLACK PERSON; COMORBIDITY; DEVELOPING COUNTRY; DIGESTIVE SYSTEM CANCER; DRUG ABSORPTION; ENTEROPATHY; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MALNUTRITION; MICROBIOME; NON COMMUNICABLE DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITION; NUTRITIONAL DISORDER; PATHOGENESIS; PEPTIC ULCER; PRIORITY JOURNAL; TOXIC HEPATITIS;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HUMANS; LIVER DISEASES; MICROBIOTA; NUTRITION DISORDERS;

EID: 84906048145     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000260     Document Type: Article

References (89)

1. Fernando N, Holton J, Zulu I, et al. Helicobacter pylori infection in an urban Zambian population. J Clin Microbiol. 2001;39:1323-1327.
2. Lake-Bakaar G, Elsakr M, Hagag N, et al. Changes in parietal cell structure and function in HIV disease. Dig Dis Sci. 1996;41:1398-1408.
3. Kelly P, Shawa T, Mwanamakondo S, et al. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micro-nutrient supplementation during a randomised controlled trial. BMC Gas-troenterol. 2010;10:72.
4. Belitsos PC, Greenson JK, Yardley JH, et al. Association of gastric hypoacidity with opportunistic enteric infections in patients with AIDS. J Infect Dis. 1992;166:277-284.
5. Humphrey JH. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet. 2009;374:1032-1035.
6. Guerrant RL, DeBoer MD, Moore SR, et al. The impoverished gut-a triple burden of diarrhea, stunting and chronic disease. Nat Rev Gastro-enterol Hepatol. 2013;10:220-229.
7. Menzies IS, Zuckerman MJ, Nukajam WS, et al. Geography of intestinal permeability and absorption. Gut. 1999;44:483-489.
8. Kelly P, Menzies I, Crane R, et al. Responses of small intestinal architecture and function over time to environmental factors in a tropical population. Am J Trop Med Hyg. 2004;70:412-419.
9. Prendergast A, Kelly P. Enteropathies in the developing world; neglected effects on global health. Am J Trop Med Hyg. 2012;86:756-763.
10. Costiniuk CT, Angel JB. HIV and the gastrointestinal immune system: does highly active antiretroviral therapy restore gut immunity? Mucosal Immunol. 2012;5:596-604.
11. Parkin DM, Ferlay M, Hamdi-Cherif F, et al. Cancer in Africa. Epidemiology and Prevention. Lyon, France: International Agency for Research on Cancer World Health Organization Scientific Publication No. 153. IARC Press; 2003.
12. Ferlay J, Shin H, Bray F, et al, Estimates of World burden of Cancer in 2008: GLOBOCAN. Int J Cancer. 2010;127:2893-2917.
13. Persson EC, Shiels MS, Dawsey SM, et al. Increased risk of stomach and esophageal malignancies in persons with AIDS. Gastroenterology. 2012; 143:943-950.
14. Asombang AW, Kelly P. Gastric cancer in Africa: what do we know about incidence and risk factors? Trans R Soc Trop Med Hyg. 2012;106: 69-74.
15. Kelly P, Katema M, Amadi B, et al. Gastrointestinal pathology in the University Teaching Hospital, Lusaka, Zambia-review of endoscopic and pathology records. Trans R Soc Trop Med Hyg. 2008;102:194-199.
16. Kayamba V, Asombang AW, Mudenda V, et al. Gastric adenocarcinoma in Zambia: a case-control study of HIV, lifestyle risk factors, and bio-markers of pathogenesis. S Afr Med J. 2013;103:255-259.
17. Hessol NA, Pipkin S, Schwarcz S, et al. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 2007;165:1143-1153.
18. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59-67.
19. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728-736.
20. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23: 2337-2345.
21. Stebbing J, Krown SE, Bower M, et al. Primary esophageal carcinoma in the era of highly active antiretroviral therapy. Arch Intern Med. 2010; 170:203-207.
22. Gallagher B, Wang Z, Schymura MJ, et al. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol. 2001;154:544-556.
23. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645-1654.
24. Adebamowo CA, Casper C, Bhatia K, et al. Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low-and middle-income countries in Africa. JAcquir Immunie Defic Syndr. 2014; 67(suppl 1):S17-S26.
25. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the DA:D study. Arch Intern Med. 2006;166:1632-1641.
26. Kovari H, Sabin CA, Ledergerber B, et al. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis. 2013;56:870-879.
27. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590-598.
28. Ocama P, Katwere M, Piloya T, et al. The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci. 2008;8:8-12.
29. Stabinski L, Reynolds SJ, Ocama P, et al. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther. 2011;16:405-411.
30. Maida I, Nunez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr. 2006;42:177-182.
31. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with dida-nosine: a nested case-control study. Clin Infect Dis. 2009;49:626-635.
32. Saves M, Vandentorren S, Daucort V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS. 1999;13:F115-F121.
33. Nunez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:426-431.
34. Reisler RB, Han C, Burman WJ, et al. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr. 2003; 34:379-386.
35. Servoss JC, Kitch DW, Andersen JW, et al. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr. 2006;43:320-323.
36. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
37. Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23-31.
38. Ocama P, Castelnuovo B, Kamya MR, et al. Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int JSTD AIDS. 2010;21:553-557.
39. Mbougua JB, Laurent C, Kouanfack C, et al. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health. 2010;10:105.
40. Moore E, Beadsworth MB, Chaponda M, et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect. 2010;61:155-163.
41. Langlois-Klassen D, Kipp W, Rubaale T. Who's talking? Communication between health providers and HIV-infected adults related to herbal medicine for AIDS treatment in western Uganda. Soc Sci Med. 2008;67:165-176.
42. Auerbach BJ, Reynolds SJ, Lamorde M, et al. Traditional herbal medicine use associated with liver fibrosis in rural Rakai, Uganda. PLoS One. 2012;7:e41737.
43. Chaudhry AA, Sulkowski MS, Chander G, et al. Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med. 2009; 10:133-142.
44. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799-805.
45. Ndububa DA, Ojo OS, Adetiloye VA, et al. The contribution of alcohol to chronic liver disease in patients from South-west Nigeria. Niger J Clin Pract. 2010;13:360-364.
46. Neuman MG, Schneider M, Nanau RM, et al. Alcohol consumption, progression of disease and other comorbidities, and responses to antiretroviral medication in people living with HIV. AIDS Res Treat. 2012;2012:751827.
47. WHO. Gender, alcohol and culture: an international study (GENACIS). WHO. Available at: http://www.who.int/substance-abuse/activities/genacis/en/index. html. Accessed October 1, 2013.
48. Chibanda D, Benjamin L, Weiss HA, Abas M. Mental, neurological, and substance use disorders in people living with HIV/AIDS in low-and middle-income countries. J Acquir Immunie Defic Syndr. 2014;67(suppl 1):S54-S67.
49. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47:250-257.
50. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50:464-473.
51. Rivero-Juárez A, Camacho A, Merchante N, et al. Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS One. 2013;8:e68953.
52. Ingiliz P, Valantin MA, Duvivier C, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology. 2009;49:436-442.
53. Ali Mk, Magee MJ, Dave JA, et al. HIV and metabolic, body, and bone disorders: what we know from low-and middle-income countries. J Acquir Immunie Defic Syndr. 2014;67(suppl 1):S27-S39.
54. Shrivastav S, Kino T, Cunningham T, et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of per-oxisome proliferator-activated receptor (gamma) and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol En-docrinol. 2008;22:234-247.
55. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179-185.
56. Abu-Shanab A, Quigley EMM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:691-701.
57. Stepanova M, Hossain N, Afendy A, et al. Hepatic gene expression of Caucasian and African-American patients with obesity-related nonalcoholic fatty liver disease. Obes Surg. 2010;20:640-50.
58. Brau N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocel-lular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527-537.
59. Kew MC. Hepatocellular carcinoma in developing countries: prevention, diagnosis and treatment. World J Hepatol. 2012;4:99-104.
60. Kew MC, Dos Santos HA, Sherlock S. Diagnosis of primary cancer of the liver. Br Med J. 1971;4:408-411.
61. Levy JI, Geddes EW, Kew MC. The chest radiograph in primary liver cancer: an analysis of 449 cases. S Afr Med J. 1976;50:1323-1326.
62. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526.
63. Castera L, Winnock M, Pambrun E, et al. Comparison of transient elas-tography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Med. 2014;15:30-9.
64. Koethe JR, Lukusa A, Giganti MJ, et al. Association between weight gain and clinical outcomes among malnourished adults initiating antire-troviral therapy in Lusaka, Zambia. JAIDS. 2010;53:507-513.
65. Fergusson P, Tomkins A. HIV prevalence and mortality among children undergoing treatment for severe acute malnutrition in sub-Saharan Africa: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2009;103:541-548.
66. Wanke CA, Silva M, Knox TA, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;31:803-805.
67. Berhe N, Tegabu D, Alemayehu M. Effect of nutritional factors on adherence to antiretroviral therapy among HIV-infected adults: a case control study in Northern Ethiopia. BMC Infect Dis. 2013;13:233.
68. Andrade CS, Jesus RP, Andrade TB, et al. Prevalence and characteristics associated with malnutrition at hospitalization among patients with acquired immunodeficiency syndrome in Brazil. PLoS One. 2012;7:e48717.
69. Trehan I, O'Hare BA, Phiri A, et al. Challenges in the management of HIV-infected malnourished children in sub-Saharan Africa. AIDS Res Treat. 2012;article ID:790786.
70. De Maayer T, Saloojee H. Clinical outcomes of severe malnutrition in a high tuberculosis and HIV setting. Arch Dis Child. 2011;96:560-564.
71. Grobler L, Nutritional interventions for reducing morbidity and mortality in people with HIV (Review). Cochrane Database Syst Rev. 2013;2:CD004536.
72. World Health Organization. Antiretroviral therapy (ART) coverage among all age groups. Available at: http://www.who.int/gho/hiv/epidemic- response/ART-text/en/index.html. Accessed November 2013.
73. Callens SFJ, Shabani N, Lusiama J, et al. Mortality and associated factors after initiation of pediatric antiretroviral treatment in the Democratic Republic of the Congo. Pediatr Infect Dis J. 2009;28:35-40.
74. Naidoo R, Rennert W, Lung A, et al. The influence of nutritional status on the response to HAART in HIV-infected children in South Africa. Pediatr Infect Dis J. 2010;29:511-513.
75. Taye B, Shiferaw S, Enquselassie F. The impact of malnutrition in survival of HIV infected children after initiation of antiretroviral treatment (ART). Ethiop Med J. 2010;48:1-10.
76. Musoke PM, Fergusson P. Severe malnutrition and metabolic complications of HIV-infected children in the antiretroviral era: clinical care and management in resource-limited settings. Am J Clin Nutr. 2011;94: 1716S-1720S.
77. Gsponer T, Weigel R, Davies MA, et al; IeDEA Southern Africa. Variability of growth in children starting antiretroviral treatment in southern Africa. Pediatrics. 2012;130:e966-e977.
78. Kim MH, Cox C, Dave A, et al. Prompt initiation of ART with therapeutic food is associated with improved outcomes in HIV-infected Malawian children with malnutrition. J Acquir Immune Defic Syndr. 2012;59:173-176.
79. Sunguya BF, Poudel KC, Mlunde LB, et al. Ready to Use Therapeutic Foods (RUTF) improves undernutrition among ART-treated, HIV-positive children in Dar es Salaam, Tanzania. Nutr J. 2012;11:60.
80. Ndekha MJ, van Oosterhout JJ, Zijlstra EE, et al. Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial. BMJ. 2009;338:b1867.
81. Tang AM, Lanzillotti J, Hendricks K, et al. Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy. AIDS. 2005;19:847-861.
82. Koethe JR, Blevins M, Bosire C, et al. Self-reported dietary intake and appetite predict early treatment outcome among low-BMI adults initiating HIV treatment in sub-Saharan Africa. Public Health Nutr. 2013;16:549-558.
83. Irlam JH, Visser MM, Rollins NN, et al. Micronutrient supplementation in children and adults with HIV infection. Cochrane Database Syst Rev. 2010;12:CD003650.
84. Kelly P, Katubulushi M, Todd J, et al. Micronutrient supplementation has a limited effect on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial. Am J Clin Nutr. 2008;88:1010-1017.
85. Jiang S, He J, Zhao X, et al. The effect of multiple micronutrient supplementation on mortality and morbidity of HIV-infected adults: a meta-analysis of randomized controlled trials. J Nutr Sci Vitaminol (Tokyo). 2012;58:105-112.
86. Zeng L, Zhang L. Efficacy and safety of zinc supplementation for adults, children and pregnant women with HIV infection: systematic review. Trop Med Int Health. 2011;16:1474-1482.
87. Heikens GT, Bunn J, Amadi B, et al. Case management of HIV-infected, severely malnourished children in sub-Saharan Africa: challenges in the area if highest prevalence. Lancet. 2008;371:1305-1307.
88. Kelly P. Nutrition, intestinal defence, and the microbiome. Proc Nutr Soc. 2010;69:261-268.
89. Kerac M, Bunn J, Seal A, et al. Probiotics and prebiotics for severe acute malnutrition (PRONUT study): a double-blind efficacy randomised controlled trial in Malawi. Lancet. 2009;374:136-144.